PMX53, a molecule antagonist that specifically blocks the interaction of C5a with C5aR32, has undergone clinical trials for the potential treatment of inflammatory disorders, including rheumatoid arthritis and psoriasis. This evidence concerns the gene C5AR1 and psoriasis.